Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study tracks how melanoma patients use a smartphone app during targeted treatment

NCT ID NCT04911998

Knowledge-focused Sponsor: Pierre Fabre Medicament Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study followed about 400 adults with advanced BRAF-mutant melanoma who were taking targeted therapy (BRAF/MEK inhibitors) and using a smartphone app called TavieSkin. The goal was to describe patient characteristics, how they used the app, their quality of life, and treatment satisfaction. No new treatments were given; researchers simply collected data from app users across several European countries.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

400 people

The number who actually took part.

Started

Feb 2021

Finished

Mar 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients diagnosed with BRAF-mutant (documented as per routine practice) unresectable or metastatic melanoma in the target countries (France, Portugal, Belgium, Spain, Germany, Italy) and initiating BRAFi/MEKi combination therapy will be invited by its healthcare provider (i.e. oncologist, dermatologist, nurse…) to use the TavieSkin app during a routine visit.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Only patients starting to use the TavieSkin app will be eligible for enrollment in the survey. The patient should meet all the following inclusion criteria to be eligible for participating: * Male or female aged ≥18 years at diagnosis of unresectable or metastatic melanoma; * Diagnosis of histologically or cytologically confirmed BRAF-mutant melanoma that is metastatic or unresectable, documented as per routine practice * Patient having an ongoing prescription of one of the three commercially available BRAFi/MEKi combination therapy, at any line of treatment * Patient using the TavieSkin app and having signed an informed consent (e-consent via the app) for data collection , according to local regulations Exclusion Criteria: Patients will be excluded from the survey if they fulfil any of the following criteria: * Patients with other BRAFi/MEKi combination than those available on the market * Patient receiving a BRAFi/MEKi combination in the adjuvant setting * Patients under guardianship because of mental illness or any other reason * Patients treated with a treatment that is not licensed for local use (including approved BRAFi/MEKi combination associated with another product)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BRAF V600 mutation are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

melanoma metastatic melanoma Neoplasm Metastasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BRAF V600 mutation Melanoma (skin) Metastatic melanoma

Contacts and locations

Locations

  • Hospital Evora

    Evora, Portugal

More trials for these conditions

Other studies related to the condition(s) this trial covers.